TY - JOUR
T1 - Cardiovascular magnetic resonance for suspected cardiac amyloidosis
T2 - where are we now?
AU - Saad, Jean Michel
AU - Ahmed, Ahmed Ibrahim
AU - Han, Yushui
AU - Malahfji, Maan
AU - Aljizeeri, Ahmed
AU - Al-Mallah, Mouaz H.
N1 - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/9
Y1 - 2022/9
N2 - Cardiac amyloidosis (CA) is an underdiagnosed form of restrictive cardiomyopathy leading to a rapid progression into heart failure. Evaluation of CA requires a multimodality approach making use of echocardiography, cardiac magnetic imaging (CMR), and nuclear imaging. With superior tissue characterization, high-resolution imaging, and precise cardiac assessment, CMR has emerged as a versatile tool in the workup of cardiac amyloidosis with a wide array of parameters both visual and quantitative. This includes late gadolinium enhancement patterns, T1/T2 mapping, and extracellular volume (ECV) measurement providing robust diagnostic accuracies, patient stratification, and prognostication. Recent advancements have introduced new measures able to identify early disease, track disease progression, and response to therapy positioning CMR as an instrumental imaging modality in the era of rising interest in CA screening and emerging effective therapies.
AB - Cardiac amyloidosis (CA) is an underdiagnosed form of restrictive cardiomyopathy leading to a rapid progression into heart failure. Evaluation of CA requires a multimodality approach making use of echocardiography, cardiac magnetic imaging (CMR), and nuclear imaging. With superior tissue characterization, high-resolution imaging, and precise cardiac assessment, CMR has emerged as a versatile tool in the workup of cardiac amyloidosis with a wide array of parameters both visual and quantitative. This includes late gadolinium enhancement patterns, T1/T2 mapping, and extracellular volume (ECV) measurement providing robust diagnostic accuracies, patient stratification, and prognostication. Recent advancements have introduced new measures able to identify early disease, track disease progression, and response to therapy positioning CMR as an instrumental imaging modality in the era of rising interest in CA screening and emerging effective therapies.
KW - CMR
KW - Cardiac amyloidosis
KW - ECV
KW - LGE
KW - T1 mapping
KW - T2 mapping
KW - Predictive Value of Tests
KW - Magnetic Resonance Spectroscopy
KW - Humans
KW - Gadolinium
KW - Amyloidosis/diagnostic imaging
KW - Magnetic Resonance Imaging, Cine
KW - Cardiomyopathies/diagnostic imaging
KW - Magnetic Resonance Imaging
KW - Contrast Media
KW - Myocardium/pathology
UR - http://www.scopus.com/inward/record.url?scp=85125646027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125646027&partnerID=8YFLogxK
U2 - 10.1007/s10741-022-10226-w
DO - 10.1007/s10741-022-10226-w
M3 - Review article
C2 - 35246774
AN - SCOPUS:85125646027
SN - 1382-4147
VL - 27
SP - 1543
EP - 1548
JO - Heart Failure Reviews
JF - Heart Failure Reviews
IS - 5
ER -